MesotheliomaSupport: Fix: remove unused ref definition causing reference error

2026-04-11T12:49:53Z

Fix: remove unused ref definition causing reference error

← Older revision		Revision as of 12:49, 11 April 2026
Line 235:		Line 235:
	<ref name="dandell_biomarkers">[https://dandell.com/mesothelioma/diagnosis/biomarkers/ Mesothelioma Blood Biomarkers], Danziger & De Llano</ref>		<ref name="dandell_biomarkers">[https://dandell.com/mesothelioma/diagnosis/biomarkers/ Mesothelioma Blood Biomarkers], Danziger & De Llano</ref>
	<ref name="pmc_chinese">Guo et al. (2017). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567857/ Diagnostic accuracy in mesothelioma: Chinese reference center review], PubMed Central</ref>		<ref name="pmc_chinese">Guo et al. (2017). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567857/ Diagnostic accuracy in mesothelioma: Chinese reference center review], PubMed Central</ref>
	~~<ref name="mesotheliomaattorney">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/ Mesothelioma Diagnosis Guide], MesotheliomaAttorney.com</ref>~~
	</references>		</references>

MesotheliomaSupport: New patient-facing diagnosis page — diagnostic journey from symptoms through specialist referral

2026-04-11T12:33:14Z

New patient-facing diagnosis page — diagnostic journey from symptoms through specialist referral

New page

{{#seo:
|title=Mesothelioma Diagnosis: What to Expect from First Symptoms to Confirmed Results
|description=Learn what happens during a mesothelioma diagnosis — from initial symptoms and imaging to biopsy, pathology results, and next steps. Patient-centered guide with verified medical data.
|keywords=mesothelioma diagnosis, mesothelioma biopsy, mesothelioma misdiagnosis, mesothelioma CT scan, mesothelioma pathology, mesothelioma second opinion, pleural mesothelioma diagnosis, peritoneal mesothelioma diagnosis
|author=David Foster, Executive Director of Client Services, Danziger & De Llano
|published_time=2026-04-11
}}
{| class="infobox" style="width:280px; float:right; margin:0 0 1em 1em; border:2px solid #1a5276; border-radius:8px; overflow:hidden;"
|-
! colspan="2" style="background:#1a5276; color:white; padding:12px; font-size:1.1em; text-align:center;" | Mesothelioma Diagnosis
|-
| colspan="2" style="padding:10px; text-align:center; font-style:italic; border-bottom:1px solid #dee2e6;" | Patient Diagnostic Journey
|-
| style="padding:10px; font-weight:bold; width:40%; border-bottom:1px solid #dee2e6;" | Category
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Medical / Diagnosis
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Typical Timeline
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''3–6 months''' (symptoms to confirmed diagnosis)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Misdiagnosis Rate
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''~25%''' of patients
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Gold Standard Test
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Thoracoscopic biopsy (92–95% sensitivity)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Most Common Subtype
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Epithelioid (~69%)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Most Common Symptom
| style="padding:10px; border-bottom:1px solid #dee2e6;" | Shortness of breath (60–90%)
|-
| style="padding:10px; font-weight:bold;" | Asbestos Latency
| style="padding:10px;" | '''30–45 years'''
|-
| colspan="2" style="background:#1a5276; padding:10px; text-align:center;" | [https://dandell.com/contact-us/ Free Case Review →]
|}

== Executive Summary ==

Receiving a '''mesothelioma diagnosis''' typically takes '''3 to 6 months''' from the first symptoms to a confirmed pathology result.<ref name="gregorio" /> The process involves multiple steps — physical examination, imaging scans, tissue biopsy, and laboratory analysis — each narrowing the possibilities until the diagnosis is confirmed. Approximately '''25% of patients''' receive an incorrect initial diagnosis, most commonly pneumonia, lung cancer, or chronic obstructive pulmonary disease, because mesothelioma shares symptoms with many common conditions.<ref name="mlc_misdiagnosis" />

The single most important diagnostic test is a '''tissue biopsy'''. Fluid samples alone confirm mesothelioma in only about '''35% of cases''', while thoracoscopic biopsy — where a small camera is inserted into the chest — achieves '''92–95% accuracy'''.<ref name="dandell_biopsy" /><ref name="pmc_cytology" /> After the tissue is obtained, a pathologist examines it to determine the specific subtype: epithelioid, sarcomatoid, or biphasic. The subtype directly affects treatment options and prognosis. Epithelioid '''pleural mesothelioma''', the most common form, has a 5-year survival rate of approximately '''20% when diagnosed at a localized stage'''.<ref name="seer" />

Because misdiagnosis is common and the disease is rare — roughly '''3,000 new cases''' are diagnosed annually in the United States — seeking evaluation at an '''NCI-designated cancer center''' with mesothelioma experience significantly improves diagnostic accuracy and treatment planning.<ref name="nci" />

== At-a-Glance ==

'''Mesothelioma diagnosis at a glance:'''

* '''3–6 months''' — typical time from first symptoms to confirmed mesothelioma diagnosis, though patients with known asbestos exposure histories receive faster referrals (median 120 vs. 214 days)<ref name="gregorio" />
* '''25% misdiagnosis rate''' — nearly 1 in 4 pleural mesothelioma patients receive an incorrect initial diagnosis, most commonly pneumonia or lung cancer<ref name="mlc_misdiagnosis" />
* '''60–90% of patients''' present with shortness of breath and nonpleuritic chest wall pain as their first symptoms<ref name="mesonet_symptoms" />
* '''Pleural effusion''' (fluid around the lungs) is found in 74–84% of patients at initial examination<ref name="dandell_symptoms" />
* '''Thoracoscopic biopsy''' is the gold standard, achieving 92–95% sensitivity compared to 35% for fluid cytology alone<ref name="pmc_cytology" />
* '''CT-guided core needle biopsy''' achieves 93% diagnostic yield as a less invasive alternative when thoracoscopy is not feasible<ref name="dandell_biopsy" />
* '''PET-CT scans''' reach approximately 95% sensitivity for distinguishing malignant from benign pleural disease<ref name="pmc_petct" />
* '''Epithelioid subtype''' accounts for approximately 69% of cases and responds best to surgery and chemotherapy<ref name="mesonet_subtypes" />
* '''Second opinions''' change the diagnosis in up to 21% of cases — mesothelioma specialists overturn 30–65% of original diagnoses from non-specialist centers<ref name="mlc_second_opinion" />
* '''30–45 years''' — the average latency period between asbestos exposure and mesothelioma diagnosis<ref name="dandell_latency" />

== Key Facts ==

{| class="wikitable" style="width:100%; margin:1em 0; border-collapse:collapse; border:2px solid #1a5276;"
|-
! style="background:#1a5276; color:white; padding:12px; text-align:left; width:40%;" | Measure
! style="background:#1a5276; color:white; padding:12px; text-align:left;" | Finding (Source)
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Diagnostic timeline
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''Median 6.5 months''' from symptom onset to first specialist visit — Gregorio et al. 2022 (PMC9496203)<ref name="gregorio" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Misdiagnosis rate
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''14% in well-resourced countries''', up to 50% in limited settings — J Thorac Oncol 2023<ref name="mlc_misdiagnosis" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Thoracoscopy sensitivity
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''92–95% sensitivity''', ~100% specificity — VATS gold standard<ref name="dandell_biopsy" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Fluid cytology sensitivity
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''~35% for mesothelioma''' (optimal 50 mL sample) — cannot subtype or assess invasion<ref name="pmc_cytology" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | CT sensitivity
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''68% sensitivity, 78% specificity''' for pleural malignancy<ref name="pmc_petct" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | PET-CT sensitivity
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''~95% sensitivity, 82% specificity''' for malignant vs. benign pleural lesions<ref name="pmc_petct" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Epithelioid prevalence
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''~69% of all mesothelioma cases''' — best prognosis of the three subtypes<ref name="mesonet_subtypes" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Pleural mesothelioma 5-year survival (localized)
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''~20%''' — drops to ~8% for advanced/distant disease (SEER data)<ref name="seer" />
|-
| style="padding:10px; font-weight:bold; border-bottom:1px solid #dee2e6;" | Second opinion impact
| style="padding:10px; border-bottom:1px solid #dee2e6;" | '''21% of patients''' receive a completely new diagnosis after expert review<ref name="mlc_second_opinion" />
|-
| style="padding:10px; font-weight:bold;" | Annual new cases (U.S.)
| style="padding:10px;" | '''~3,000''' pleural mesothelioma diagnoses per year — National Cancer Institute<ref name="nci" />
|}

== What Symptoms Lead to a Mesothelioma Workup? ==

Most mesothelioma diagnoses begin when a patient visits their doctor for persistent respiratory symptoms. '''Shortness of breath''' and '''chest wall pain''' occur in 60–90% of pleural mesothelioma patients.<ref name="mesonet_symptoms" /> These symptoms develop gradually over weeks or months and often worsen before the patient seeks care.

Other common symptoms include persistent dry cough, unexplained weight loss, fatigue, and night sweats. For '''[[Peritoneal_Mesothelioma|peritoneal mesothelioma]]''', the symptoms are abdominal — bloating, swelling, pain, and changes in bowel habits — which are frequently mistaken for irritable bowel syndrome or, in women, ovarian cancer.<ref name="dandell_peritoneal" />

A critical detail that speeds diagnosis is '''asbestos exposure history'''. Patients who report prior asbestos exposure receive specialist referrals in a median of 120 days, compared to 214 days for those who do not mention it.<ref name="gregorio" /> If you have any history of working with or around asbestos — even decades ago — tell your doctor immediately.

== What Happens During the Imaging Workup? ==

After a physical exam, doctors order imaging tests to look for abnormalities in the chest or abdomen.

'''Chest X-ray''' is usually the first test. It can reveal pleural effusion (fluid buildup) or pleural thickening, but it cannot confirm mesothelioma. X-rays detect pleural abnormalities in about 44% of asbestos-exposed individuals.<ref name="dandell_imaging" />

'''CT scan''' provides detailed cross-sectional images and is the primary imaging tool for mesothelioma evaluation. CT achieves 68% sensitivity and 78% specificity for identifying pleural malignancy.<ref name="pmc_petct" /> It shows the location and extent of pleural thickening, any masses, and whether nearby structures are involved.

'''PET-CT scan''' combines anatomical CT images with metabolic activity data. It reaches approximately '''95% sensitivity''' for distinguishing malignant from benign pleural disease and is especially useful for determining whether the cancer has spread to lymph nodes or distant sites.<ref name="pmc_petct" /> However, false positives can occur from tuberculosis pleurisy or prior pleurodesis procedures.

'''MRI''' is sometimes ordered when CT results are inconclusive about chest wall or diaphragm invasion. MRI achieves 100% sensitivity for detecting diaphragmatic invasion compared to 93–94% for CT.<ref name="dandell_imaging" />

Imaging alone cannot confirm mesothelioma. A '''tissue biopsy''' is always required.

== How Is Mesothelioma Confirmed by Biopsy? ==

Biopsy — removing a tissue sample for laboratory examination — is the only way to definitively diagnose mesothelioma. Several biopsy methods exist, and the choice depends on the tumor's location and the patient's overall health.

'''Thoracentesis or paracentesis''' (fluid drainage) is often the first procedure performed when effusion is present. A needle draws fluid from the chest or abdomen for analysis. While useful for symptom relief, fluid cytology confirms mesothelioma in only about '''35% of cases''' and cannot determine the histological subtype.<ref name="pmc_cytology" /> Sarcomatoid mesothelioma does not shed cells into fluid, making cytology completely non-diagnostic for that subtype.

'''CT-guided core needle biopsy''' uses imaging to guide a needle directly into the tumor. This achieves a '''93% diagnostic yield''' and is less invasive than surgery.<ref name="dandell_biopsy" /> The tract seeding risk (cancer cells spreading along the needle path) is approximately 4%.

'''Thoracoscopy (VATS)''' is the '''gold standard'''. A surgeon inserts a small camera and instruments through small incisions in the chest wall. This achieves '''92–95% sensitivity''' with near-100% specificity and provides enough tissue for complete pathological analysis.<ref name="dandell_biopsy" /> Complications are uncommon — major complications occur in less than 2% of cases with local anesthetic thoracoscopy.

'''Laparoscopy''' serves the same purpose for '''[[Peritoneal_Mesothelioma|peritoneal mesothelioma]]''', allowing direct visualization of the abdominal lining and tissue sampling. It changes the surgical treatment plan in up to 25% of cases.<ref name="dandell_peritoneal" />

== What Do the Pathology Results Mean? ==

After biopsy, a pathologist examines the tissue under a microscope to confirm the diagnosis and determine the '''histological subtype'''. This step is critical because the subtype directly influences treatment options and expected outcomes. For the full technical reference on immunohistochemistry markers, staging systems, and molecular testing, see '''[[Mesothelioma_Diagnosis_and_Staging]]'''.

'''Epithelioid mesothelioma''' accounts for approximately '''69% of cases'''. It is the most responsive to surgery and chemotherapy and carries the best prognosis. Calretinin, the primary immunohistochemistry marker, is positive in 93% of epithelioid cases.<ref name="mesonet_subtypes" />

'''Sarcomatoid mesothelioma''' is the most aggressive subtype, accounting for roughly 10–15% of cases. It is harder to diagnose because it resembles other spindle-cell tumors, and standard IHC markers are less reliable. Sarcomatoid '''pleural mesothelioma''' has a 2-year survival rate of approximately 15%.<ref name="mesonet_subtypes" />

'''Biphasic mesothelioma''' contains both epithelioid and sarcomatoid cells. Prognosis depends on the ratio — cases with a higher proportion of epithelioid cells respond better to treatment.

Pathology results typically take '''7–14 days''' after biopsy. If your initial pathology report does not specify the mesothelioma subtype, request clarification from your medical team.

== Why Are Misdiagnoses Common — and What Should You Do? ==

Mesothelioma is rare, and most community physicians encounter very few cases in their careers. The disease mimics common conditions — pneumonia, COPD, lung adenocarcinoma, and pleuritis — leading to an incorrect initial diagnosis in approximately '''25% of patients'''.<ref name="mlc_misdiagnosis" />

Expert review panels consistently overturn '''30–65% of original diagnoses''' from non-specialist centers.<ref name="mlc_second_opinion" /> A study of mesothelioma diagnoses submitted to Chinese reference centers found that only '''56.5%''' were confirmed correct upon expert review.<ref name="pmc_chinese" />

If you receive a mesothelioma diagnosis — or suspect your current diagnosis may be wrong — '''seek a second opinion''' at an NCI-designated cancer center with mesothelioma specialists. Research shows that '''21% of patients''' who sought a second opinion received a completely new diagnosis.<ref name="mlc_second_opinion" />

== What Happens After a Confirmed Diagnosis? ==

Once mesothelioma is confirmed, several steps follow in rapid sequence:

'''Staging workup''' determines how far the cancer has spread. Additional imaging (PET-CT, MRI) helps classify the disease by the TNM staging system. Staging directly determines which treatments are available — early-stage patients may qualify for surgery, while advanced-stage cases are typically treated with systemic therapy. For detailed staging information, see '''[[Mesothelioma_Diagnosis_and_Staging]]'''.

'''Treatment team assembly''' brings together the specialists who will manage your care: a thoracic surgeon (or surgical oncologist for peritoneal cases), a medical oncologist, a radiation oncologist, a pulmonologist, and a palliative care specialist. NCI-designated cancer centers coordinate these specialists in multidisciplinary tumor boards.

'''[[Clinical_Trials|Clinical trial evaluation]]''' should happen early. Eligibility for trials often depends on being treatment-naive (not yet having started chemotherapy), so discuss trial options before beginning standard treatment.

'''Legal consultation''' is appropriate at diagnosis. Mesothelioma is caused by asbestos exposure, and [[Asbestos_Trust_Funds|compensation from asbestos trust funds]], civil lawsuits, and VA benefits may be available to help cover treatment costs and lost income.

== Frequently Asked Questions ==

'''How long does it take to get a mesothelioma diagnosis?'''

The typical diagnostic timeline is 3 to 6 months from first symptoms to confirmed pathology results. A 2022 study found a median of 6.5 months from symptom onset to first specialist visit, followed by an additional 1.5 months to histopathological diagnosis.<ref name="gregorio" /> Patients who report asbestos exposure history to their doctors receive faster referrals.

'''Can mesothelioma be diagnosed from a blood test?'''

No blood test can confirm mesothelioma. Blood biomarkers such as mesothelin (MESOMARK) and fibulin-3 can support a diagnosis and monitor disease progression, but they cannot replace tissue biopsy for definitive confirmation. For details on blood biomarkers, see '''[[Mesothelioma_Diagnosis_and_Staging]]'''.<ref name="dandell_biomarkers" />

'''What is the difference between this page and Mesothelioma Diagnosis and Staging?'''

This page covers the '''patient experience''' — what to expect from symptoms through confirmed diagnosis and next steps. '''[[Mesothelioma_Diagnosis_and_Staging]]''' is a technical reference covering immunohistochemistry marker panels, TNM staging tables, molecular testing, and blood biomarker assays in detail.

'''Why is mesothelioma so often misdiagnosed?'''

Mesothelioma is rare (~3,000 cases annually in the U.S.) and its symptoms — shortness of breath, chest pain, fatigue — overlap with common conditions. Most community physicians rarely see mesothelioma, making initial misdiagnosis as pneumonia, COPD, or lung cancer common. Specialist evaluation at an NCI-designated center significantly improves diagnostic accuracy.<ref name="mlc_misdiagnosis" />

'''Should I get a second opinion?'''

Yes. Research shows that 21% of mesothelioma patients who sought a second opinion received a completely different diagnosis, and expert panels overturn 30–65% of original diagnoses from non-specialist centers.<ref name="mlc_second_opinion" /> If your diagnosis was made at a community hospital without mesothelioma experience, a second opinion from a specialist center is strongly recommended.

'''Does the mesothelioma subtype affect my treatment options?'''

Yes. Epithelioid mesothelioma (~69% of cases) responds best to surgery and chemotherapy. Sarcomatoid mesothelioma is more aggressive but has shown improved outcomes with immunotherapy — nivolumab plus ipilimumab more than doubled median survival compared to chemotherapy alone in the CheckMate 743 trial.<ref name="mesonet_subtypes" /> Your pathology report should specify the subtype.

== Quick Statistics ==

* '''3–6 months''' — typical time from first symptoms to confirmed diagnosis<ref name="gregorio" />
* '''~3,000''' new pleural mesothelioma diagnoses annually in the United States<ref name="nci" />
* '''25%''' of patients receive an incorrect initial diagnosis<ref name="mlc_misdiagnosis" />
* '''92–95%''' sensitivity for thoracoscopic biopsy (gold standard)<ref name="dandell_biopsy" />
* '''~35%''' sensitivity for fluid cytology alone<ref name="pmc_cytology" />
* '''69%''' of mesothelioma cases are the epithelioid subtype<ref name="mesonet_subtypes" />
* '''~20%''' 5-year survival rate for localized pleural mesothelioma (SEER data)<ref name="seer" />
* '''21%''' of patients receive a new diagnosis after seeking a second opinion<ref name="mlc_second_opinion" />
* '''30–45 years''' — average latency between asbestos exposure and diagnosis<ref name="dandell_latency" />
* '''120 vs. 214 days''' — referral time for patients who report vs. do not report asbestos exposure history<ref name="gregorio" />

== Get Help ==


If you or a loved one has been diagnosed with mesothelioma, experienced attorneys at Danziger & De Llano can help you understand your legal options and pursue compensation to cover treatment costs. Call [https://dandell.com/ Danziger & De Llano] for a free, confidential case evaluation. You can also take the [https://mesotheliomalawyersnearme.com/quiz/ free case assessment quiz] to identify potential compensation sources.


== Related Pages ==

* '''[[Mesothelioma_Diagnosis_and_Staging]]''' — Technical reference: IHC markers, TNM staging, biomarkers, molecular testing
* '''[[Pleural_Mesothelioma]]''' — The most common mesothelioma type
* '''[[Peritoneal_Mesothelioma]]''' — Abdominal mesothelioma diagnosis and treatment
* '''[[Mesothelioma_Specialists]]''' — Finding experienced mesothelioma physicians
* '''[[Clinical_Trials]]''' — Current mesothelioma clinical trial opportunities
* '''[[Asbestos_Trust_Funds]]''' — Compensation for mesothelioma patients

== References ==
<references>
<ref name="gregorio">Gregorio et al. (2022). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496203/ Diagnostic delay in malignant pleural mesothelioma: A systematic review], PMC9496203</ref>
<ref name="mlc_misdiagnosis">[https://mesotheliomalawyercenter.org/mesothelioma/diagnosis/ Mesothelioma Diagnosis], Mesothelioma Lawyer Center</ref>
<ref name="dandell_biopsy">[https://dandell.com/mesothelioma/diagnosis/ Mesothelioma Diagnosis & Biopsy], Danziger & De Llano</ref>
<ref name="pmc_cytology">Hjerpe et al. (2018). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088535/ Cytological diagnosis of mesothelioma: An IMIG guideline], PubMed Central</ref>
<ref name="seer">[https://seer.cancer.gov/statistics-network/explorer/application.html SEER Cancer Statistics Explorer], National Cancer Institute</ref>
<ref name="nci">[https://www.cancer.gov/types/mesothelioma Mesothelioma Treatment], National Cancer Institute</ref>
<ref name="mesonet_symptoms">[https://mesothelioma.net/mesothelioma-symptoms/ Mesothelioma Symptoms], Mesothelioma.net</ref>
<ref name="dandell_symptoms">[https://dandell.com/mesothelioma/symptoms/ Mesothelioma Symptoms & Warning Signs], Danziger & De Llano</ref>
<ref name="pmc_petct">Flores et al. (2014). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280922/ Presentation, staging, and imaging of mesothelioma], PubMed Central</ref>
<ref name="dandell_imaging">[https://dandell.com/mesothelioma/diagnosis/imaging/ Mesothelioma Imaging & Diagnosis], Danziger & De Llano</ref>
<ref name="mesonet_subtypes">[https://mesothelioma.net/mesothelioma-cell-types/ Mesothelioma Cell Types & Subtypes], Mesothelioma.net</ref>
<ref name="mlc_second_opinion">[https://mesotheliomalawyercenter.org/mesothelioma/second-opinion/ Getting a Second Opinion for Mesothelioma], Mesothelioma Lawyer Center</ref>
<ref name="dandell_peritoneal">[https://dandell.com/mesothelioma/peritoneal/ Peritoneal Mesothelioma], Danziger & De Llano</ref>
<ref name="dandell_latency">[https://dandell.com/mesothelioma/latency-period/ Mesothelioma Latency Period], Danziger & De Llano</ref>
<ref name="dandell_biomarkers">[https://dandell.com/mesothelioma/diagnosis/biomarkers/ Mesothelioma Blood Biomarkers], Danziger & De Llano</ref>
<ref name="pmc_chinese">Guo et al. (2017). [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567857/ Diagnostic accuracy in mesothelioma: Chinese reference center review], PubMed Central</ref>
<ref name="mesotheliomaattorney">[https://mesotheliomaattorney.com/mesothelioma/diagnosis/ Mesothelioma Diagnosis Guide], MesotheliomaAttorney.com</ref>
</references>

[[Category:Medical]]
[[Category:Diagnosis]]
[[Category:Mesothelioma]]
[[Category:Treatment]]
[[Category:Patient Resources]]
[[Category:Imaging]]
[[Category:Biopsy]]
[[Category:Pathology]]

Mesothelioma Diagnosis - Revision history

MesotheliomaSupport: Fix: remove unused ref definition causing reference error

MesotheliomaSupport: New patient-facing diagnosis page — diagnostic journey from symptoms through specialist referral